Price
5,395
+1.65%52W Range
Market Cap
₹2,607.31 Cr
Traded: ₹0.62 Cr (0.02%) 0.0x
Free Float: ₹529.02 Cr (0.12% of FF traded)
Volume · 60D trend
1.16 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
57 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +13.0% | +27.0% | +21.0% | -- | +19.0% | Decelerating |
| ROE | +28.0% | +31.0% | +29.0% | -- | -- | Stable |
| Return | +39.0% | +65.0% | +52.0% | +15.0% | -- | Decelerating |
| Profit | +35.0% | +120.0% | +24.0% | -- | +30.0% | Stable |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 143 | 120 | 116 | 118 | 117 | 100 | 95 | 102 | 100 | 81 | 76 | 84 | 79 | 69 |
| Expenses | 100 | 86 | 82 | 78 | 80 | 68 | 69 | 72 | 69 | 56 | 55 | 61 | 56 | 48 |
| Operating Profit | 43 | 34 | 34 | 40 | 37 | 32 | 26 | 30 | 31 | 24 | 21 | 23 | 23 | 21 |
| OPM % | 30.0% | 28.0% | 30.0% | 34.0% | 32.0% | 32.0% | 27.0% | 29.0% | 31.0% | 30.0% | 27.0% | 28.0% | 29.0% | 30.0% |
| Other Income | 2 | 2 | 3 | 1 | 1 | 0 | 2 | 2 | 0 | 2 | 1 | 1 | 0 | 0 |
| Interest | 3 | 2 | 2 | 4 | 4 | 3 | 4 | 4 | 3 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 11 | 12 | 12 | 11 | 11 | 10 | 10 | 9 | 10 | 8 | 7 | 6 | 6 | 2 |
| Profit Before Tax | 31 | 21 | 23 | 26 | 23 | 19 | 14 | 19 | 19 | 17 | 13 | 17 | 16 | 18 |
| Tax % | 24.0% | 24.0% | 26.0% | 25.0% | 26.0% | 14.0% | 26.0% | 26.0% | 25.0% | 26.0% | 26.0% | 24.0% | 26.0% | 25.0% |
| Net Profit | 23 | 16 | 17 | 19 | 17 | 16 | 10 | 14 | 14 | 13 | 9 | 13 | 12 | 14 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 48.4 | 33.6 | 35.8 | 40.0 | 36.7 | 34.0 | 22.1 | 30.1 | 30.0 | 27.2 | 20.1 | 26.8 | 24.6 | 29.1 |
| Sales Growth (YoY) | -- | 20.2% | 22.2% | 15.2% | 16.9% | 23.7% | 25.2% | 21.5% | 27.3% | 16.3% | 19.5% | 22.3% | 18.3% | 24.7% |
| Sales Growth (QoQ) | -- | 3.5% | -1.7% | 0.8% | 17.0% | 5.3% | -6.9% | 2.0% | 23.5% | 6.6% | -9.5% | 6.3% | 14.5% | -- |
| OP Growth (YoY) | 16.2% | 6.3% | 30.8% | 33.3% | 19.4% | 33.3% | 23.8% | 30.4% | 34.8% | 14.3% | -- | -- | -- | -- |
| OP Growth (QoQ) | 26.5% | 0.0% | -15.0% | 8.1% | 15.6% | 23.1% | -13.3% | -3.2% | 29.2% | 14.3% | -8.7% | 0.0% | 9.5% | -- |
| Profit Growth (YoY) | -- | 1.6% | 66.2% | 36.5% | 22.3% | 25.0% | 10.2% | 12.4% | 22.3% | -6.5% | 86.6% | 38.8% | 26.7% | 99.1% |
| EPS Growth (YoY) | -- | -1.2% | 61.6% | 32.8% | 22.3% | 25.0% | 10.2% | 12.4% | 22.3% | -6.5% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | -6.0% | -10.6% | 8.9% | 7.9% | 53.7% | -26.5% | 0.3% | 10.3% | 35.4% | -25.0% | 9.1% | -15.7% | -- |
| OP Margin | -- | 28.3% | 29.3% | 33.9% | 31.6% | 32.0% | 27.4% | 29.4% | 31.0% | 29.6% | 27.6% | 27.4% | 29.1% | 30.4% |
| Net Margin | -- | 13.3% | 14.7% | 16.1% | 14.5% | 16.0% | 10.5% | 13.7% | 14.0% | 16.1% | 11.8% | 15.5% | 15.2% | 20.3% |
| Material Cost % | -- | 9.3% | 10.1% | 10.1% | 10.5% | 10.7% | 10.7% | 10.7% | 10.2% | 10.3% | 10.6% | 11.3% | 10.0% | 11.5% |
| Employee Cost % | -- | 20.0% | 20.7% | 18.2% | 19.0% | 20.0% | 22.0% | 19.5% | 17.6% | 19.1% | 20.4% | 19.5% | 20.9% | 20.2% |
| P/S | 5.25 | 5.14 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 34.21 | 34.28 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 7.54 | 6.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Newspaper Advertisement published for the 32nd Annual General Meeting is submitted.
Notice convening the 32nd Annual General Meeting of the members of the Company which is scheduled to be held on September 09, 2026, is submitted.
The record date for the payment of final dividend for the financial year 2025-26 is submitted.
Annual Report of Dr. Agarwal's Eye Hospital Limited for the financial year 2025-26 is submitted
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Invesco Mutual Fund
Unaudited Financial Results for the quarter ended June 30, 2026, is submitted.
Certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018, is submitted
Voting results of the Hon''ble NCLT convened meeting of the Unsecured Creditors of Dr. Agarwal''s Eye Hospital Limited is submitted.
Summary of the proceedings of the Hon''ble NCLT convened meeting of the unsecured creditors of Dr. Agarwal''s Eye Hospital Limited is submitted.
Summary of the proceedings of the Honble NCLT convened meeting of the secured creditors of Dr. Agarwal''s Eye Hospital Limited held on July 02, 2026, is submitted.
Voting results of the Hon''ble NCLT convened meeting of the Secured Creditors of Dr. Agarwal''s Eye Hospital Limited is submitted.
The voting results of the Hon''ble NCLT convened meeting of the Equity Shareholders of Dr. Agarwal''s Eye Hospital Limited is submitted. The resolution set out in the notice have been duly ....
Summary of proceedings of the NCLT convened meetings of the Equity Shareholders of Dr. Agarwal''s Eye Hospital Limited held on July 02, 2026 is submitted.
Disclosure on Closure of Trading Window is submitted.
Re-affirmation and withdrawal of Credit Rating by CRISIL Ratings Limited with respect to the debt facilities availed by the Company is submitted.
Joint Newspaper Advertisement of the NCLT convened meetings of the Equity Shareholders, Secured Creditors and Unsecured Creditors of the Company, is submitted.
Letter providing direct weblink and a Static Quick Response Code to the Notice of the Equity Shareholders and Creditors dispatched by the Company, is submitted.
Notice convening the meeting of the unsecured creditors of the Company pursuant to the order of the Hon''ble Tribunal, Chennai Bench, is submitted.
Notice convening the meeting of the Secured Creditors of the Company pursuant to the order of the Hon''ble NCLT, Chennai Bench.
Notice convening the Meeting of the Equity Shareholders of the Company pursuant to the Order of Honb''le NCLT, Chennai Bench, is submitted.
Audited Financial Results For The Quarter And Year Ended March 31, 2026 And Declaration of Final Dividend for the financial year ended March 31, 2026, is attached
Audited Financial Results of the Company for the quarter and year ended March 31, 2026, is attached.
Declaration of Final Dividend of Rs 4/- per equity share of Rs. 10 each for the financial year ended March 31, 2026.
Dr Agarwals Eye Hospital Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2026 ,inter alia, to consider and approve The Audited Financial ....
Receipt of Order passed by the Hon''ble NCLT, Chennai Bench, in relation to the Scheme of Amalgamation between Dr. Agarwal''s Eye Hospital Limited and Dr. Agarwal''s Health Care Limited, is attached.
Intimation regarding the trading and admission to dealings of the Company''s Equity Shares on the National Stock Exchange of India Limited, is attached.
Disclosure under Regulation 74(5) of SEBI (DP) Regulations is submitted.
Disclosure on closure of trading window is submitted.
Issuance of Credit Rating by ICRA Limited with respect to the debt facilities availed by the Company, is enclosed.
Receipt of the observation letter from BSE Limited conveying ''no adverse observations'' in relation to the Scheme of Amalgamation of Dr. Agarwal''s Eye Hospital Limited and Dr. Agarwal''s ....
Unaudited financial results for the quarter and nine months ended December 31, 2025, is submitted.
The disclosure on shifting of registered office of the Company within the local limits of the city of Chennai is submitted.
Unaudited financial results for the quarter and nine months ended December 31, 2025, is submitted
Dr Agarwals Eye Hospital Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2026 ,inter alia, to consider and approve the unaudited financial ....
As per the letter enclosed.
As per the letter enclosed
Approval of Interim Dividend of Rs.3 per equity share for the financial year 2025-26.
As per the letter enclosed.
As per letter enclosed.
Dr Agarwals Eye Hospital Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2025 ,inter alia, to consider and approve Update on board meeting
As per letter enclosed.
Dr Agarwals Eye Hospital Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2025 ,inter alia, to consider and approve the un-audited financial ....
As per the letter enclosed.
As per the letter enclosed.
As per the letter enclosed.
31st Annual General Meeting (AGM) - Results of Remote e-voting and E-voting at the AGM along with the Scrutinizer''s Report is enclosed.
Proceedings of the 31st Annual General Meeting of the Company is enclosed.
As per the letter enclosed.
As per the letter enclosed.
As per the letter enclosed.
Held by ETFs
1 ETFs hold dragarwq · sorted by weight
Held by Mutual Funds
3 schemes hold dragarwq · sorted by weight